{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:14:49Z","timestamp":1773216889368,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021267","name":"ANZ Breast Cancer Trials Group Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001559","name":"Breast Cancer Foundation NZ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.breast.2025.104586","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:17:52Z","timestamp":1758784672000},"page":"104586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-5604","authenticated-orcid":false,"given":"Julia","family":"Dixon-Douglas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney T.","family":"Van Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Savas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104586_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2025.104586_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104586_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104586_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104586_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104586_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","article-title":"Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial","volume":"27","author":"Bachelot","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2025.104586_bib7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.104586_bib8","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","author":"Badve","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.104586_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000510812","article-title":"Understanding PD-L1 testing in breast cancer: a practical approach","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2025.104586_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2017.08.010","article-title":"PD-L1 in breast cancer: comparative analysis of 3 different antibodies","volume":"72","author":"Karnik","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.breast.2025.104586_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100257","article-title":"Refining patient selection for breast cancer immunotherapy: beyond PD-L1","volume":"6","author":"Kossai","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104586_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001558","article-title":"Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers","volume":"8","author":"Rozenblit","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.breast.2025.104586_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis","volume":"99","author":"Boman","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2025.104586_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oncolo\/oyad212","article-title":"Baseline tumor size as prognostic index in patients with advanced solid tumors receiving experimental targeted agents","volume":"29","author":"Nicol\u00f2","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2025.104586_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.08.026","article-title":"Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents","volume":"139","author":"Tarantino","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104586_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.breast.2025.104586_bib17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2025.104586_bib18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/cancers16091748","article-title":"Programmed death ligand-1 and tumor burden score dictate treatment responses in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"16","author":"Lien","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.104586_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"sup>18F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma","volume":"60","author":"Ito","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2025.104586_bib20","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00262-021-03108-x","article-title":"Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 \u2265 50% non-small cell lung cancer patients treated with first-line pembrolizumab","volume":"71","author":"Bureau","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.breast.2025.104586_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.breast.2025.104586_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cac2.12420","article-title":"High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway","volume":"43","author":"Wen","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.breast.2025.104586_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2025.104586_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2025.01.002","article-title":"Factors associated with short- and long-term survival in metastatic HER2-positive breast cancer","volume":"25","author":"Leone","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104586_bib25","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.annonc.2020.03.273","article-title":"173P Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: a review of the charactHER clinical data","volume":"31","author":"Skrobo","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104586_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall survival of CDK4\/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.104586_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4048\/jbc.2020.23.e37","article-title":"Concordance of programmed death-ligand 1 expression between SP142 and 22C3\/SP263 assays in triple-negative breast cancer","volume":"23","author":"Lee","year":"2020","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2025.104586_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.breast.2025.104586_bib29","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221180","article-title":"FDG PET\/CT prognostic markers in patients with advanced melanoma treated with ipilimumab and nivolumab","volume":"307","author":"Iravani","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2025.104586_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98310-3","article-title":"FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy","volume":"11","author":"Flaus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2025.104586_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06394-y","article-title":"[18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab","author":"Seban","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625006034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625006034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:32:10Z","timestamp":1773138730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625006034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0960977625006034"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104586","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104586"}}